Athira Pharma Management
Management criteria checks 0/4
Athira Pharma's CEO ist Mark Litton , ernannt in Oct 2021, hat eine Amtszeit von 2.17 Jahren. Die jährliche Gesamtvergütung beträgt $3.78M , bestehend aus 14.4% Gehalt und 85.6% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.39% der Aktien des Unternehmens, im Wert von $305.26K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 1.5 Jahre bzw. 2 Jahre.
Key information
Mark Litton
Chief executive officer
US$3.8m
Total compensation
CEO salary percentage | 14.4% |
CEO tenure | 2.5yrs |
CEO ownership | 0.05% |
Management average tenure | 1.9yrs |
Board average tenure | 2.4yrs |
Recent management updates
Recent updates
Will Athira Pharma (NASDAQ:ATHA) Spend Its Cash Wisely?
Feb 16Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?
Nov 02Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?
May 29Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans?
Jan 04Athira Alzheimer's drug trial gets monitoring panel nod to continue after efficacy analysis
Oct 17Athira Pharma GAAP EPS of -$0.65
Aug 15We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely
Aug 09Athira Pharma: The Market Is Missing A Potential New Alzheimer's Drug
Jun 22Companies Like Athira Pharma (NASDAQ:ATHA) Are In A Position To Invest In Growth
May 08We're Not Very Worried About Athira Pharma's (NASDAQ:ATHA) Cash Burn Rate
Jan 11Athira Pharma: What, Exactly, Did The CEO Do?
Jun 29Athira Pharma falls after the decision to place CEO on temporary leave
Jun 17Athira surges after Jefferies estimated 50% gain on FDA approval for Biogen’s Alzheimer’s therapy
Jun 07We Think Athira Pharma (NASDAQ:ATHA) Can Afford To Drive Business Growth
May 24We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely
Feb 08Athira: Early Stage Alzheimer's Therapeutics With An Interesting Approach
Jan 11Here's What Athira Pharma, Inc.'s (NASDAQ:ATHA) Shareholder Ownership Structure Looks Like
Dec 18Athira Pharma nabs research grant of $15M from NIH
Dec 08Athira Pharma reports Q3 results
Nov 12CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | n/a | n/a | -US$118m |
Sep 30 2023 | n/a | n/a | -US$121m |
Jun 30 2023 | n/a | n/a | -US$108m |
Mar 31 2023 | n/a | n/a | -US$102m |
Dec 31 2022 | US$4m | US$543k | -US$96m |
Sep 30 2022 | n/a | n/a | -US$82m |
Jun 30 2022 | n/a | n/a | -US$77m |
Mar 31 2022 | n/a | n/a | -US$67m |
Dec 31 2021 | US$3m | US$450k | -US$55m |
Sep 30 2021 | n/a | n/a | -US$46m |
Jun 30 2021 | n/a | n/a | -US$39m |
Mar 31 2021 | n/a | n/a | -US$27m |
Dec 31 2020 | n/a | n/a | -US$20m |
Sep 30 2020 | n/a | n/a | -US$13m |
Jun 30 2020 | n/a | n/a | -US$6m |
Mar 31 2020 | n/a | n/a | -US$6m |
Dec 31 2019 | US$204k | US$12k | -US$5m |
Vergütung im Vergleich zum Markt: MarkDie Gesamtvergütung ($USD3.78M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD738.70K).
Entschädigung vs. Einkommen: MarkDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.
CEO
Mark Litton (55 yo)
2.5yrs
Tenure
US$3,775,199
Compensation
Dr. Mark J. Litton, Ph D., MBA, serves as Director at Lumen Bioscience, Inc. since October 2020. He served as Chief Operating Officer of Athira Pharma, Inc. since July 2019 until October 18, 2021 and serve...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | 2.5yrs | US$3.78m | 0.051% $ 49.2k | |
Chief Development Officer & COO | 2.5yrs | US$2.03m | 0.035% $ 33.5k | |
CFO & Chief Business Officer | less than a year | no data | 0.22% $ 209.5k | |
Chief Scientific Officer | 1.3yrs | US$135.32k | 0.21% $ 200.6k | |
Head of Investor Relations | no data | no data | no data | |
General Counsel & Corporate Secretary | 2.8yrs | US$2.71m | 0.090% $ 86.1k | |
Chief People Officer | less than a year | no data | no data |
1.9yrs
Average Tenure
55yo
Average Age
Erfahrenes Management: ATHADas Führungsteam des Unternehmens gilt nicht als erfahren ( 1.5 Jahre durchschnittliche Betriebszugehörigkeit), was auf ein neues Team schließen lässt.
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | 2.5yrs | US$3.78m | 0.051% $ 49.2k | |
Independent Director | 9.3yrs | US$140.56k | 0.52% $ 500.9k | |
Independent Director | 2.3yrs | US$265.96k | 0.067% $ 64.5k | |
Independent Chairwoman of the Board | 3.3yrs | US$166.56k | 0.10% $ 95.8k | |
Independent Director | 3.9yrs | US$138.06k | 14.1% $ 13.5m | |
Chairman of Scientific Advisory Board | 1.8yrs | US$2.10m | 0.24% $ 228.7k | |
Member of Scientific Advisory Board | 1.8yrs | no data | no data | |
Independent Director | 3.1yrs | US$147.06k | 0% $ 0 | |
Independent Director | 2.1yrs | US$263.54k | 0% $ 0 | |
Independent Director | 3.7yrs | US$149.06k | 0.013% $ 12.5k | |
Member of Scientific Advisory Board | 1.8yrs | no data | no data | |
Member of Scientific Advisory Board | 1.8yrs | no data | no data |
2.4yrs
Average Tenure
62.5yo
Average Age
Erfahrener Vorstand: ATHADie Vorstandsmitglieder gelten nicht als erfahren ( 2 Jahre durchschnittliche Amtszeit), was auf einen neuen Vorstand hindeutet.